66th ASH Annual Meeting: 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Optimizing Outcomes in Adult Patients

Symposia: Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities Oral and Poster Abstracts
Oral

Research, Clinical trials, Clinical Practice (Health Services and Quality), Clinical Research, Health disparities research, Treatment Considerations, Real-world evidence, Technology and Procedures, Measurable Residual Disease

Room 6CF (San Diego Convention Center)

Moderators:

Kris Michael Mahadeo, MD, Duke University and Rusha Bhandari, MD, MS, City of Hope

Disclosures:

No relevant conflicts of interest to declare.

This session will explore novel preparative regimens and clinical strategies to improve supportive care and patient outcomes among Adult patients undergoing allogeneic transplantation.

2:00 PM

265

CLAG-M or FLAG-Ida Followed Immediately By Allogeneic Hematopoietic Cell Transplantation for Adults with Relapsed/Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasm

Filippo Milano, MD^1,2, Brenda M. Sandmaier, MD³, Mary-Elizabeth M. Percival, MD^4,5, Sarah M Mahan⁶^*, Laura C Roberts⁶^*, Raya Mawad, MD^2,6, Anna B. Halpern, MD^2,6, Madi Brunette⁶^*, Cristina Maria Ghiuzeli, MD^2,6, Jacob S. Appelbaum, MD, PhD^4,7, Naveed Ali, MD, MBBS^2,6 and Roland B. Walter, MD, PhD, MS⁶

¹Fred Hutchinson Cancer Research Center, Seattle, WA
²University of Washington, Seattle, WA
³Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA
⁴Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA
⁵Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA
⁶Fred Hutchinson Cancer Center, Seattle, WA
⁷University of Washington School of Medicine, Seattle, WA

2:15 PM

266

Elevated Dosing of Recombinant Human Thrombopoietin Accelerates Platelet Engraftment in Allogeneic Hematopoietic Stem Cell Transplantation: A Prospective, Dosage-Optimization, Controlled Clinical Study

Dan Feng^*, Qingzhen Liu^*, Qiaoling MA^* and Erlie Jiang

State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences &Peking Union Medical College, Tianjin, China

2:30 PM

267

Long-Term Follow up of a Prospective Pilot Study of an α/β T-Lymphocyte Depleted Graft Conditioned with a Reduced Intensity Regimen in Patients with Hematologic Malignancies

Charlotte FM Hughes, MD, FRACP, FRCPA¹, Richard J. Lin, MD, PhD^1,2, Sean M. Devlin, PhD³^*, Brian C. Shaffer, MD, MS^1,2, Ann A. Jakubowski, MD, PhD^1,2, Vishwamber Talla¹^*, Amethyst Saldia, BS¹^*, Boglarka Gyurkocza, MD^1,2, Esperanza B. Papadopoulos, MD^1,2, Sergio A. Giralt, MD^1,2, Elena Maryamchik, MD⁴^*, Miguel-Angel Perales, MD^1,2 and Roni Tamari, MD^1,2

¹Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY
²Department of Medicine, Weill Cornell Medical College, New York, NY
³Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY
⁴Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

2:45 PM

268

Epstein-Barr Virus Reactivation and Post-Transplant Lymphoproliferative Disorders after Allo-HSCT in the Era of Letermovir for Cytomegalovirus Prophylaxis

Jingtao Huang¹^*, Jing Zhou²^*, Shixuan Zhang³^*, Ruoxuan Zhang²^*, Zengkai Pan⁴^*, Luxiang Wang, MD, PhD⁴^*, Chuanhe Jiang, MD, PhD⁴^*, Jiayu Huang⁴^*, Zilu Zhang, MD, PhD⁴^*, Yanmin Zhao³^*, Yang Cao⁵^*, Jianmin Wang, MD, PhD⁶ and Xiaoxia Hu⁴^*

¹Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, Nati, Shanghai, China
²Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
³Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
⁴Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
⁵Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, San Diego, CA
⁶Changhai Hospital, Shanghai, China

3:00 PM

269

Safety of 20Gy Total Marrow Irradiation Based Conditioning Regimen for Hematopoietic Cell Transplantation with T Cell Adoptive Immunotherapy

Francesco Zorutti, MD¹^*, Simonetta Saldi, MD²^*, Loredana Ruggeri, MD, PhD³^*, Valerio Viglione, MD¹^*, Christian Fulcheri⁴^*, Rebecca Sembenico, MD¹^*, Matteo Caridi, MD¹^*, Anna Castaldo, MD¹^*, Antonella Mancusi, PhD¹^*, Claudio Zucchetti²^*, Susanta Hui, PhD⁵^*, Federico Camilli⁶^*, Tiziana Zei³^*, Roberta Iacucci Ostini³^*, Enrico Karim Jardini³^*, Eni Hoxha¹^*, Antonella Monaldi³^*, Anthony S. Stein, MD^7,8, Gianluca Ingrosso¹^*, Andrea Velardi, MD, PhD¹^*, Massimo Fabrizio Martelli, MD, PhD¹^*, Maria Paola Martelli, MD, PhD^1,3^*, Cynthia Aristei, MD²^*, Alessandra Carotti, MD³^* and Antonio Pierini, MD, PhD¹^*

¹Department of Medicine and Surgery, Division of Hematology and Clinical Immunology, University of Perugia, Perugia, Italy
²Department of Medicine and Surgery, Radiation Oncology Section, University of Perugia, Perugia, Italy
³Department of Medicine and Surgery, Division of Hematology and Clinical Immunology, S. Maria della Misericordia Hospital, Perugia, Italy
⁴Department of Medicine and Surgery, Radiation Oncology Section, S. Maria della Misericordia Hospital, Perugia, Italy
⁵Radiation Oncology, City of Hope National Medical Center, Duarte, CA
⁶Department of Medicine and Surgery, Radiation Oncology Section, Santa Maria della Misericordia Hospital, Perugia, Italy
⁷Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA
⁸City of Hope Cancer Center, Duarte, CA

3:15 PM

270

Safety and Efficacy of VA Combined with Modified BuCy Conditioning Regimen Followed By Allo-HSCT for High-Risk or Refractory/Relapsed Acute Lymphoblastic Leukemia : A Prospective, Single-Center, Single-Arm Clinical Trial

Xiaoqian Chen^*, Wei Cui^*, Qingya Cui^*, Zheng Li, MD^*, Sifan Chen^*, Mengyun Li^*, Xuekai Li^*, Juan Chen^*, Yan Yu^*, Xin Zhang^*, Depei Wu, MD, PhD and Xiaowen Tang^*

National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

721.O2.6 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Optimizing Outcomes in Adult Patients